A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Conditions:   Asthma;   Chronic Obstructive Pulmonary Disease (COPD)
Interventions:   Drug: AZD7594 inhalation powder (200 ?g);   Drug: AZD7594 inhalation powder (400 ?g);   Drug: AZD7594 pressurized inhalation suspension (200 ?g);   Drug: AZD7594 placebo inhalation powder;   Drug: AZD7594 placebo pressurized inhalation suspension
Sponsor:   AstraZeneca
Not yet recruiting – verified December 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK-Abello A/S, Originator or ALK HDM Tablets in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites (HDM)

Conditions:   Allergy;   Asthma;   Rhinitis
Interventions:   Drug: Mitizax;   Drug: Placebo
Sponsors:   Abbott;   Linical Co., Ltd;   Datamap
Recruiting – verified November 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK-Abello A/S, Originator or ALK HDM Tablets (ALK HDM Tablets) in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites (HDM)

Conditions:   Allergy;   Asthma;   Rhinitis
Interventions:   Drug: Mitizax;   Drug: Placebo
Sponsors:   Abbott;   Linical Co., Ltd;   Datamap
Recruiting – verified November 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects

Conditions:   Asthma (Part 1);   COPD (Part 2)
Interventions:   Drug: Dose 1, AZD8871 50 ?g (Part 1);   Drug: Dose 2, AZD8871 100 ?g (Part 1);   Drug: Dose 3, AZD8871 300 ?g (Part 1);   Drug: Dose 4, AZD8871 600 µg (Part 1);   Drug: Dose 5, AZD8871 1200 µg (Part 1);   Drug: Dose 6, AZD8871 1800 ?g (Part 1);   Drug: Placebo, AZD8871 placebo (Part 1);   Drug: Treatment A, AZD8871 dose A (Part 2);   Drug: Treatment B, AZD8871 dose B (Part 2);   Drug: Treatment C, Indacaterol 150 ?g (Part 2);   Drug: Treatment D, Tiotropium 18 ?g (Part 2)
Sponsor:   AstraZeneca
Not yet recruiting – verified October 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days